Updated AJCC/TNM Staging Better Predictor of Survival in Thyroid Cancer


The updated staging system results in 36% of patients being reclassified to a lower stage, reducing overdiagnosis.

Evert van Velsen, MD, MSc, and colleagues in the Netherlands have found that the 8th edition of the American Joint Committee on Cancer/Tumor Node Metastasis (AJCC/TNM) staging system is superior to the 7th edition with regards to predicting overall survival (OS) and disease specific survival (DSS) in those with papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC).Click through the slides below for details on their study and take home points for clinical practice.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.